PACIRA BIOSCIENCES, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
PACIRA BIOSCIENCES, INC. (PCRX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $9.36 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2018-02-28
- PACIRA BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-12-31 was $4.82M, a 24.75% decline year-over-year.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-09-30 was -$6.01M, a 302.53% decline year-over-year.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-06-30 was $11.61M.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-03-31 was -$1.06M.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2017 was $9.36M, a 1218.17% increase from fiscal 2016.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2016 was $710.00K, a 92.08% decline from fiscal 2015.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2015 was $8.97M, a 41.59% decline from fiscal 2014.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was $15.35M, a 59.52% increase from fiscal 2013.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$1.19M derived: sum of 2 quarters · filed 2018-02-28 | $10.41M derived: sum of 3 quarters · filed 2018-02-28 | $9.36M 10-K · filed 2018-02-28 | ||||
| 2017-09-30 | -$6.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $5.60M derived: sum of 2 quarters · filed 2017-11-08 | $4.54M 10-Q · filed 2017-11-08 | $10.94M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2017-06-30 | $11.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $10.55M 10-Q · filed 2017-08-02 | $16.95M derived: sum of 3 quarters · filed 2018-02-28 | $19.92M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2017-03-31 | -$1.06M 10-Q · filed 2017-05-04 | $5.34M derived: sum of 2 quarters · filed 2018-02-28 | $8.31M derived: sum of 3 quarters · filed 2018-02-28 | $5.88M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $9.37M derived: sum of 2 quarters · filed 2018-02-28 | $6.94M derived: sum of 3 quarters · filed 2018-02-28 | $710.00K 10-K · filed 2018-02-28 | ||||
| 2016-09-30 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $536.00K derived: sum of 2 quarters · filed 2017-11-08 | -$5.69M 10-Q · filed 2017-11-08 | $2.17M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-06-30 | -$2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$8.66M 10-Q · filed 2017-08-02 | -$792.00K derived: sum of 3 quarters · filed 2018-02-28 | -$1.87M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-03-31 | -$6.23M 10-Q · filed 2017-05-04 | $1.64M derived: sum of 2 quarters · filed 2018-02-28 | $557.00K derived: sum of 3 quarters · filed 2018-02-28 | $8.42M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2015-12-31 | $7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $6.78M derived: sum of 2 quarters · filed 2018-02-28 | $14.64M derived: sum of 3 quarters · filed 2018-02-28 | $8.97M 10-K · filed 2018-02-28 | $9.94M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $6.78M derived: sum of 2 quarters · filed 2016-11-02 | $1.10M 10-Q · filed 2016-11-02 | $2.03M 10-Q · filed 2015-10-27 | $16.45M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $7.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $2.18M 10-Q · filed 2016-08-04 | $5.02M 10-Q · filed 2015-07-30 | $17.53M derived: sum of 3 quarters · filed 2017-03-01 | $21.86M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | -$5.68M 10-Q · filed 2016-05-02 | -$4.32M 10-Q · filed 2015-04-30 | $9.67M derived: sum of 2 quarters · filed 2017-03-01 | $14.00M derived: sum of 3 quarters · filed 2017-03-01 | $20.76M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $15.35M 10-K · filed 2017-03-01 | $19.68M derived: sum of 2 quarters · filed 2017-03-01 | $26.44M derived: sum of 3 quarters · filed 2017-03-01 | $15.35M 10-K · filed 2016-02-25 | $14.25M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $4.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $11.09M derived: sum of 2 quarters · filed 2015-10-27 | $9.56M 10-Q · filed 2015-10-27 | $10.18M 10-Q · filed 2014-10-30 | $12.76M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-06-30 | $6.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $5.23M 10-Q · filed 2015-07-30 | $8.43M derived: sum of 3 quarters · filed 2016-02-25 | $11.59M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | -$1.53M 10-Q · filed 2015-04-30 | $1.67M derived: sum of 2 quarters · filed 2016-02-25 | $4.83M derived: sum of 3 quarters · filed 2016-02-25 | $7.93M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $6.36M derived: sum of 2 quarters · filed 2016-02-25 | $9.46M derived: sum of 3 quarters · filed 2016-02-25 | $9.62M 10-K · filed 2016-02-25 | $10.24M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $6.26M derived: sum of 2 quarters · filed 2014-10-30 | $6.42M 10-Q · filed 2014-10-30 | $958.00K derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $3.26M 10-Q · filed 2014-07-31 | -$2.20M derived: sum of 3 quarters · filed 2015-02-24 | $5.90M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $162.00K 10-Q · filed 2014-05-01 | -$5.30M derived: sum of 2 quarters · filed 2015-02-24 | $2.80M derived: sum of 3 quarters · filed 2015-02-24 | $2.16M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | -$5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $2.64M derived: sum of 2 quarters · filed 2015-02-24 | $2.00M derived: sum of 3 quarters · filed 2015-02-24 | $1.39M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $8.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $7.46M derived: sum of 2 quarters · filed 2013-10-31 | $6.85M 10-Q · filed 2013-10-31 | $8.70M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | -$643.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$1.26M 10-Q · filed 2013-08-06 | $596.00K derived: sum of 3 quarters · filed 2014-02-25 | $1.22M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | -$613.00K 10-Q · filed 2013-05-08 | $1.24M derived: sum of 2 quarters · filed 2014-02-25 | $1.86M derived: sum of 3 quarters · filed 2014-02-25 | $1.11M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $2.47M derived: sum of 2 quarters · filed 2014-02-25 | $1.72M derived: sum of 3 quarters · filed 2014-02-25 | $2.55M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $620.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$131.00K derived: sum of 2 quarters · filed 2012-11-01 | $697.00K 10-Q · filed 2012-11-01 | |||||
| 2011-06-30 | -$751.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $77.00K 10-Q · filed 2012-08-09 | ||||||
| 2011-03-31 | $828.00K 10-Q · filed 2012-05-09 | |||||||
| 2010-12-31 | -$1.12M 10-K · filed 2013-03-07 | |||||||
| 2009-12-31 | -$4.44M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |